Skip to Content

Opzelura® 15 mg/g cream (ruxolitinib phosphate): Important information regarding presence of particles in Opzelura cream

10/06/2025
Medicines for human use Direct healthcare professional communication (DHPC)

Important Safety Information from Incyte Biosciences Distribution B.V. (“Incyte”), regarding Opzelura® 15 mg/g cream (ruxolitinib phosphate) dated 05 June 2025: Important information regarding presence of particles in Opzelura cream

Documents

Opens in new window Opzelura cream_Opzelura DHPC Letter_Ireland_with date 05.06.2025.docx PDF : 296KB | 10/06/2025